Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H26FNO3 |
Molecular Weight | 358.437 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC1=CC=C(\C=C\C2=CC=C(OCCOCCOCC[18F])C=C2)C=C1
InChI
InChIKey=NCWZOASIUQVOFA-FWZJPQCDSA-N
InChI=1S/C21H26FNO3/c1-23-20-8-4-18(5-9-20)2-3-19-6-10-21(11-7-19)26-17-16-25-15-14-24-13-12-22/h2-11,23H,12-17H2,1H3/b3-2+/i22-1
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/?term=21971456; https://www.ncbi.nlm.nih.gov/pubmed/?term=22354138
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/?term=21971456; https://www.ncbi.nlm.nih.gov/pubmed/?term=22354138
Florbetaben F18 is a18F-labeled stilbene derivative used as a tracer for PET imaging of beta-amyloid deposits in the human brain. The F 18 isotope produces a positron signal that is detected by a PET scanner. 3H-florbetaben in vitro binding experiments reveal two binding sites (Kd of 16 nM and 135 nM) in frontal cortex homogenates from patients with AD. Binding of florbetaben F18 to beta-amyloid plaques in post-mortem brain sections from patients with AD using autoradiography correlates with both immunohistochemical and Bielschowsky silver stains. Florbetaben F 18 does not bind to tau or alpha-synuclein in tissue from patients with AD. Neither Neuraceq nor non-radioactive florbetaben F 19 bind to AT8 positive tau deposits in brain tissue from patients with frontotemporal dementia (FTD), using autoradiography and immunohistochemistry, respectively.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P05067|||Q13764|||Q8WZ99 Gene ID: 351.0 Gene Symbol: APP Target Organism: Homo sapiens (Human) Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=19837759 |
3.72 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | NEURACEQ Approved UseNeuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. Launch Date2014 |
Sample Use Guides
The recommended dose is 300 MBq (8.1 mCi), maximum 30 mcg mass dose, administered as a single slow intravenous bolus (6 sec/mL) in a total volume of up to 10 mL.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/?term=19837759
Fresh-frozen and paraffin-embedded tissue from AD, FTLD-tau and DLB patients and age-matched non-demented controls were used for autoradiographic analysis. Frozen sections, sliced at a 18-μm thickness on a cryostate, and paraffin sections, sliced on a sliding microtome at a thickness of 6μm, were mounted onto glass slides. Paraffin sections were deparaffinized using routine histological methods before performing binding studies and immunohistochemistry, respectively. For autoradiography, sections were incubated with 10 Bq/μl [18F]-florbetaben (specific activity, 351 Ci/mmol) diluted in 25 mM HEPES buffer, pH 7.4, and 0.1% bovine serum albumin (BSA) (200μl/slide) for 1 h at room temperature (RT) in a humidified chamber. Autoradiographic signals were detected by a phosphoimager device (Fuji BAS5000).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
NEURACEQ (AUTHORIZED: RADIONUCLIDE IMAGING)
Created by
admin on Fri Dec 15 17:20:24 GMT 2023 , Edited by admin on Fri Dec 15 17:20:24 GMT 2023
|
||
|
NCI_THESAURUS |
C2124
Created by
admin on Fri Dec 15 17:20:25 GMT 2023 , Edited by admin on Fri Dec 15 17:20:25 GMT 2023
|
||
|
EMA ASSESSMENT REPORTS |
NEURACEQ (AUTHORIZED: ALZHEIMER DISEASE)
Created by
admin on Fri Dec 15 17:20:24 GMT 2023 , Edited by admin on Fri Dec 15 17:20:24 GMT 2023
|
||
|
NDF-RT |
N0000177914
Created by
admin on Fri Dec 15 17:20:25 GMT 2023 , Edited by admin on Fri Dec 15 17:20:25 GMT 2023
|
||
|
WHO-ATC |
V09AX06
Created by
admin on Fri Dec 15 17:20:24 GMT 2023 , Edited by admin on Fri Dec 15 17:20:24 GMT 2023
|
||
|
FDA ORPHAN DRUG |
732420
Created by
admin on Fri Dec 15 17:20:24 GMT 2023 , Edited by admin on Fri Dec 15 17:20:24 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
902143-01-5
Created by
admin on Fri Dec 15 17:20:24 GMT 2023 , Edited by admin on Fri Dec 15 17:20:24 GMT 2023
|
PRIMARY | |||
|
Florbetaben (18F)
Created by
admin on Fri Dec 15 17:20:25 GMT 2023 , Edited by admin on Fri Dec 15 17:20:25 GMT 2023
|
PRIMARY | |||
|
7769
Created by
admin on Fri Dec 15 17:20:25 GMT 2023 , Edited by admin on Fri Dec 15 17:20:25 GMT 2023
|
PRIMARY | |||
|
DTXSID20238065
Created by
admin on Fri Dec 15 17:20:24 GMT 2023 , Edited by admin on Fri Dec 15 17:20:24 GMT 2023
|
PRIMARY | |||
|
1492940
Created by
admin on Fri Dec 15 17:20:25 GMT 2023 , Edited by admin on Fri Dec 15 17:20:25 GMT 2023
|
PRIMARY | RxNorm | ||
|
TLA7312TOI
Created by
admin on Fri Dec 15 17:20:24 GMT 2023 , Edited by admin on Fri Dec 15 17:20:24 GMT 2023
|
PRIMARY | |||
|
TLA7312TOI
Created by
admin on Fri Dec 15 17:20:24 GMT 2023 , Edited by admin on Fri Dec 15 17:20:24 GMT 2023
|
PRIMARY | |||
|
m11720
Created by
admin on Fri Dec 15 17:20:25 GMT 2023 , Edited by admin on Fri Dec 15 17:20:25 GMT 2023
|
PRIMARY | |||
|
C132687
Created by
admin on Fri Dec 15 17:20:25 GMT 2023 , Edited by admin on Fri Dec 15 17:20:25 GMT 2023
|
PRIMARY | |||
|
100000143249
Created by
admin on Fri Dec 15 17:20:25 GMT 2023 , Edited by admin on Fri Dec 15 17:20:25 GMT 2023
|
PRIMARY | |||
|
SUB119774
Created by
admin on Fri Dec 15 17:20:24 GMT 2023 , Edited by admin on Fri Dec 15 17:20:24 GMT 2023
|
PRIMARY | |||
|
9184
Created by
admin on Fri Dec 15 17:20:24 GMT 2023 , Edited by admin on Fri Dec 15 17:20:24 GMT 2023
|
PRIMARY | |||
|
AB-32
Created by
admin on Fri Dec 15 17:20:25 GMT 2023 , Edited by admin on Fri Dec 15 17:20:25 GMT 2023
|
PRIMARY | |||
|
4818
Created by
admin on Fri Dec 15 17:20:24 GMT 2023 , Edited by admin on Fri Dec 15 17:20:24 GMT 2023
|
PRIMARY | |||
|
11501341
Created by
admin on Fri Dec 15 17:20:25 GMT 2023 , Edited by admin on Fri Dec 15 17:20:25 GMT 2023
|
PRIMARY | |||
|
DB09148
Created by
admin on Fri Dec 15 17:20:24 GMT 2023 , Edited by admin on Fri Dec 15 17:20:24 GMT 2023
|
PRIMARY | |||
|
79033
Created by
admin on Fri Dec 15 17:20:24 GMT 2023 , Edited by admin on Fri Dec 15 17:20:24 GMT 2023
|
PRIMARY | |||
|
CHEMBL1908906
Created by
admin on Fri Dec 15 17:20:24 GMT 2023 , Edited by admin on Fri Dec 15 17:20:24 GMT 2023
|
PRIMARY | |||
|
Florbetaben F 18
Created by
admin on Fri Dec 15 17:20:25 GMT 2023 , Edited by admin on Fri Dec 15 17:20:25 GMT 2023
|
PRIMARY | |||
|
N0000175869
Created by
admin on Fri Dec 15 17:20:25 GMT 2023 , Edited by admin on Fri Dec 15 17:20:25 GMT 2023
|
PRIMARY | Positron Emitting Activity [MoA] |
ACTIVE MOIETY
METABOLITE (PARENT)